文献速递细菌感染、耐药与抗菌药物

万古霉素或达托霉素联合抗葡萄球菌β-内酰胺对MRSA菌血症的体外协同与相加效应与死亡率的关系:CAMERA2预计划分析

Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an antistaphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: preplanned analysis from CAMERA2.
PubMed 文献 · Clin Microbiol Infect · 2026-02-10

本研究为CAMERA2随机对照试验的事后分析,纳入150例MRSA菌血症患者,评估万古霉素或达托霉素联合β-内酰胺的体外协同/相加效应与临床结局的关系。阳性相互作用组与阴性相互作用组90天死亡率无显著差异,但阳性组14天全因死亡率显著更低。作者认为结果需谨慎解读,为假设生成性。

要点

  • 阳性体外相互作用与14天全因死亡率显著降低相关。
  • 90天死亡率在阳性与阴性相互作用组间无显著差异。
  • 协同试验可能有助于优化联合治疗,但需随机试验验证。

核心结论

  • 万古霉素或达托霉素联合β-内酰胺的阳性体外相互作用与MRSA菌血症患者14天死亡率降低相关,但需谨慎解读且为假设生成性。

研究设计与样本

  • CAMERA2多中心随机试验的事后分析,纳入150例MRSA菌血症成人患者,随机接受标准治疗或联合抗葡萄球菌β-内酰胺治疗。
  • 协同试验采用微量稀释棋盘法集中检测,将患者分为阳性相互作用组(协同/相加)和阴性相互作用组(拮抗/无关)。

主要发现

  • 150例中阳性相互作用组103例,阴性相互作用组47例,患者特征相似。
  • 90天死亡率复合终点在两组间无显著差异(34% [16/47] vs. 32% [33/103],p=0.81)。
  • 阳性相互作用组第2天持续性菌血症率更高(32.0% [33/103] vs. 19.1% [9/47],p=0.10)。
  • 阳性相互作用组14天全因死亡率显著更低(2.9% [3/103] vs. 12.8% [6/47],p=0.03)。

关键数值与推荐

  • 阳性相互作用定义为协同或相加,阴性相互作用定义为拮抗或无关。
  • 主要复合终点为90天死亡率。

临床怎么用

  • 联合治疗可能在存在阳性相互作用时获益,并非普遍有效。
  • 协同试验可能有助于优化联合治疗策略,但需随机试验确认。

局限性

  • 为事后分析,样本量有限,结果需谨慎解读且为假设生成性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Combination antibiotic therapy may improve treatment success for bacterial infections, but bacterial strain-to-strain variability in synergy and its clinical impact remains unclear. This study evaluated whether positive in vitro interactions (synergy or additivity) between vancomycin or daptomycin and a β-lactam in methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections are associated with improved clinical outcomes in the Combination Antibiotic for Methicillin Resistant Staphylococcus aureus (CAMERA2) trial. METHODS: In this post hoc analysis of the multicentre randomized CAMERA2 trial, adults with MRSA bacteraemia were randomly assigned to standard care (vancomycin or daptomycin) or combination therapy with an antistaphylococcal β-lactam. Of 174 combination-therapy patients, 24 were excluded for unavailable isolates or missing outcome data, leaving 150 for analysis. Synergy testing was performed centrally, post hoc, using a microdilution checkerboard assay, stratifying patients into positive interaction (synergy/additivity) and negative interaction (antagonism/indifference) groups. Clinical outcomes-including primary composite end point of 90-day mortality-were compared between groups, using statistical tests and multivariate regression adjusting for confounders. RESULTS: Among 150 patients, 103 were in the positive interaction group and 47 in the negative interaction group. Patient characteristics were similar. The primary composite endpoint of 90-day mortality (34% [16 of 47] vs. 32% [33 of 103], p 0.81) did not differ significantly between groups. Persistent bacteraemia rate at day 2 was higher (32.0% [33 of 103] vs. 19.1% [9 of 47], p 0.10) in the positive interaction group. However, 14-day all-cause mortality was significantly lower in the positive interaction group (2.9% [3 of 103] vs. 12.8% [6 of 47], p 0.03). CONCLUSIONS: Positive interactions between vancomycin or daptomycin and a β-lactam were associated with lower 14-day mortality in MRSA bacteraemia. However, these findings should be interpreted with caution and considered hypothesis generating. Combination therapy may be beneficial when positive interactions are present, not universally effective. Synergy testing may help optimize combination therapy, warranting confirmation in a randomized trial.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Soo JZY, Lim TP, Ho JJY, et al. Effect of in vitro synergy and additivity of vancomycin or daptomycin plus an antistaphylococcal β-lactam for methicillin-resistant Staphylococcus aureus bacteraemia on mortality: preplanned analysis from CAMERA2. Clin Microbiol Infect. 2026. PMID: 41679464. doi:10.1016/j.cmi.2026.01.032

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。